Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).
Lauren C. Harshman, MD
Advertisement
Articles by Lauren C. Harshman, MD
Advertisement
Latest Updated Articles
Dr. Harshman on Earlier Use of Immunotherapy in RCCPublished: May 18th 2018 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
2
Quarter Century Update: Platform Approaches and Industry Investment
3
Quarter Century Update: How can Partnerships Between Academia, Biotech, and Pharma be Better Structured?
4
